Newbridge Financial Services Group, Inc. Affimed N.V. Transaction History

Newbridge Financial Services Group, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Sep 07, 2021	SELL	$7.78 - $11.4 $7,780 - $11,400	-1,000 Reduced 40.0%	1,500 $13,000
Q4 2020 Sep 07, 2021	BUY	$3.16 - $7.03 $4,740 - $10,545	1,500 Added 150.0%	2,500 $15,000
Q3 2020 Sep 07, 2021	BUY	$3.26 - $4.73 $3,260 - $4,730	1,000 New	1,000 $3,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.